EO2401 in vivo immune therapy + nivolumab +/- bevacizumab shows survival benefit in first recurrent glioblastomaData presented at 2025 SNO conference by lead investigator Paris, France – 2 DECEMBER ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback